Lutalyse Highcon Injection is a drug owned by ZOETIS INC. It is protected by 2 US drug patents filed in 2018. All patents have expired. Details of Lutalyse Highcon Injection’s patents and their expiration are given below.
| Drug Patent Number | Drug Patent Expiry | Status |
|---|---|---|
 | ||
| US6187818 | 17 Jun, 2018 | Expired |
Exclusivity Information
Lutalyse Highcon Injection holds 1 exclusivity out of which 1 has expired. Details of Lutalyse Highcon Injection's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCI | Aug 17, 2018 |
About Lutalyse Highcon Injection
Lutalyse Highcon Injection is a drug
owned by ZOETIS INC.
Lutalyse Highcon Injection uses
Dinoprost Tromethamine as the active
ingredient.
Active Ingredient:
Lutalyse Highcon Injection uses
Dinoprost Tromethamine as the active ingredient.
Check out other Drugs and Companies using
Dinoprost Tromethamine ingredient.